PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
EMA's CHMP Recommends BMS's Opdivo, Chemo for Neoadjuvant PD-L1-Positive NSCLC
If approved, the drug combination will be the first immunotherapy-based treatment available in the neoadjuvant setting for NSCLC patients in Europe.
OncoHost Licenses Biosensing Technology From BGN Technologies to Predict Immunotherapy Response
The Immuno-checkpoint Artificial Reporter platform has shown in studies to predict patient response to anti-PD-1 therapies across all cancer types.
Merck, Moderna's Personalized Vaccine-Keytruda Combo Shines Across Biomarker Subgroups at AACR
Premium
Adding Moderna's vaccine to Merck's checkpoint inhibitor in the adjuvant treatment setting benefited melanoma patients, even across biomarker groups like TMB and PD-L1.
European Commission Approves Libtayo in PD-L1-Positive Non-Small Cell Lung Cancer
The EC's approval is based on data from a Phase III trial showing a significant increase in overall survival and progression-free survival compared to placebo.
NICE Backs Merck's Keytruda for PD-L1-Expressing Cervical Cancer
NICE recommended that Keytruda plus chemo with or without Avastin be available in England for cervical cancers expressing PD-L1 with a combined positive score of at least 1.